5-HT3 antiemetic therapy for patients with breast cancer

Breast Cancer Research and Treatment

Volumn 57, Issue 2, 1999, Pages 207-214

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiemetic therapy; Breast cancer; Chemotherapy; Granisetron; Ondansetron; Quality of life

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; FLUOROURACIL; GRANISETRON; HISTAMINE H3 RECEPTOR ANTAGONIST; IFOSFAMIDE; METHOTREXATE; METOCLOPRAMIDE; MITOXANTRONE; NAVELBINE; ONDANSETRON; PROCHLORPERAZINE; STEROID; SEROTONIN ANTAGONIST;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; REVIEW;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; QUALITY OF LIFE; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0032585894     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006233802863     Document Type: Article

References (23)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998
2. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103-109, 1997
3. Morrow GR: Chemotherapy-related nausea and vomiting: Etiology and management. CA Cancer J Clin 39: 89-104, 1989
4. Perez EA, Hartmann LC: Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol 23(5 suppl 11): 41-45, 1996
5. Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K: A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 78: 144-151, 1996
6. De Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113: 834-840, 1990
7. Hesketh P: Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Semin Oncol 22(4 suppl 10): 19-23, 1995
8. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: Multicenter, double-blind, randomized parallel study. J Clin Oncol 16: 754-760, 1998
9. Heron JF: Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: A double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22(suppl 10): 24-30, 1995
10. Fisher B, Osborne CK, Margolesc RG, Bloomer WD: Neoplasms of the breast. In: Holland JF, Bast RC, Morton DL (eds) Cancer Medicine. Williams & Wilkins, Baltimore, MD, 1997, pp. 2349-2429
11. Tortorice PV, O'Connell MB: Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10: 129-145, 1990
12. Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J, Meisenberg BR: An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 20: 473-478, 1997
13. Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C: Comparable safety and antiemetic efficacy of a brief (30-sec bolus) intravenous granisetron infusion and a standard (15-min) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4: 52-58, 1998
14. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B: Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27: 1137-1140, 1991
15. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118: 407-413, 1993
16. Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D, Wentz A: Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest 15: 297-303, 1997
17. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C: Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15: 2966-2973, 1997
18. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Riviere A, Khayat D, Bleiberg H, Faraldi M, Claverie N: A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A: 807-813, 1996
19. Gebbia V, Cannata G, Testa A, Curio G, Valenza R, Cipolla C, Latteri MA, Gebbia N: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 74: 1945-1952, 1994
20. Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6: 805-810, 1995
21. Bleiberg HH, Spielmann M, Falkson G, Romain D: Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study. Clin Ther 17: 38-51, 1995
22. Coates A, Abraham S, Kay SB, Sowerbulls T, Frewin C, Fox RM, Tattersall MH: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203-208, 1983
23. Jenns K: Importance of nausea. Cancer Nurs 17: 488-493, 1994